End-of-day quote
Other stock markets
|
||
- CHF | - |
Apr. 18 | Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment | DJ |
Apr. 18 | ROCHE HOLDINGS AG : UBS sticks Neutral | ZD |
Sales 2024 * | 59.84B 65.55B | Sales 2025 * | 63.41B 69.46B | Capitalization | 177B 194B |
---|---|---|---|---|---|
Net income 2024 * | 13.38B 14.65B | Net income 2025 * | 14.66B 16.05B | EV / Sales 2024 * | 3.19 x |
Net Debt 2024 * | 13.47B 14.75B | Net Debt 2025 * | 7.31B 8B | EV / Sales 2025 * | 2.91 x |
P/E ratio 2024 * |
13.1
x | P/E ratio 2025 * |
11.9
x | Employees | - |
Yield 2024 * |
4.36% | Yield 2025 * |
4.54% | Free-Float | 88.91% |
Latest transcript on Roche Holding Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 65 | 95-12-31 |
1st Jan change | Capi. | |
---|---|---|
+27.97% | 676B | |
+23.58% | 554B | |
-7.02% | 349B | |
+14.85% | 318B | |
+6.25% | 291B | |
+2.96% | 210B | |
-0.41% | 204B | |
-11.81% | 144B | |
-8.80% | 142B |